Novartis stock falls after trial setbacks as HSBC lifts rating
Published on 09/10/2026 at 14:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novartis AG stock (ISIN CH0012005267) is trading higher again at 113.36 Swiss francs on the SIX Swiss Exchange as of September 10, 2026, up about 1.5% intraday after a sharp sell-off earlier in the week following two major trial failures that erased roughly 26 billion Swiss francs of market value.
Clinical setbacks trigger record share-price drop
According to Economic Times Pharma on September 10, 2026, Novartis shares closed down 10.9 percent on the prior trading day in Zurich, the worst single-day fall on record for the company, after its experimental drug for a muscle-wasting disorder failed in a late-stage study.
As Reuters reported on September 10, 2026, the failed muscle-wasting drug had been acquired through Novartis' 12 billion dollar takeover of U.S. firm Avidity, and the trial setback came just one day after disappointing results from the companys heart drug pelacarsen had already pushed the stock down about 3 percent.
Taken together, the two back-to-back trial failures wiped nearly 30 billion dollars off Novartis market value in a matter of days, illustrating how sensitive the stock is to pipeline news and intensifying pressure on the companys board and management to demonstrate that capital allocated to acquisitions and late-stage development is delivering sustainable returns.
HSBC and Deutsche Bank adjust views on Novartis stock
In the wake of the sell-off, analyst houses have moved quickly to reassess Novartis stock. According to GuruFocus on September 10, 2026, HSBC upgraded its rating on Novartis from Reduce to Hold and raised its price target from 123.00 dollars to 136.00 dollars, while describing the shares as fairly valued and trading about 5.0 percent above an intrinsic GF Value of 130.94 dollars.
On the other side of the analyst spectrum, Deutsche Bank has become more cautious. As GuruFocus reported on September 9, 2026, Deutsche Bank downgraded Novartis from Buy to Hold and cut its price target, contributing to a three-day decline of more than 13 percent in the share price as investors reacted to the clinical trial failures and the revised risk-reward view.
Further detail on HSBCs stance shows the bank expects a near-term consensus downgrade cycle but believes that the most negative catalysts from pelacarsen and the muscle-wasting program have now largely played out, shifting attention toward upcoming trial readouts such as the RECHARGE study, according to Yahoo Finance on September 10, 2026.
Q2 2026 results show modest growth and pipeline dependence
Beyond the immediate trial-related volatility, the fundamental picture from the latest quarter helps frame the debate about Novartis stock. According to Yahoo Finance on September 9, 2026, Novartis reported Q2 2026 net sales of 14.4 billion dollars, up 3 percent in reported U.S. dollars and 1 percent at constant currencies compared with the prior-year quarter.
The same Q2 2026 report shows that core operating income remained flat at 5.9 billion dollars, while GAAP net income fell 19 percent year on year to 3.3 billion dollars, highlighting that profitability is under pressure even as top-line growth is positive, according to Yahoo Finance.
Pipeline-driven products were the key growth engines in the quarter. Q2 2026 net sales growth was supported by strong contributions from cancer drug Kisqali, which grew 43 percent at constant currencies, and multiple sclerosis therapy Kesimpta, which rose 32 percent at constant currencies, again according to the Q2 2026 overview by Yahoo Finance.
Despite these double-digit product growth rates, generic competition reduced overall sales growth by 14 percentage points in Q2 2026, meaning that without loss of exclusivity effects the underlying revenue momentum would have been considerably stronger, as noted by Yahoo Finance.
For full-year 2026, Novartis has reaffirmed guidance rather than raising it, expecting low single-digit net sales growth and a low single-digit decline in core operating income, which signals cautious optimism but also suggests that margin headwinds from generics and investment in the pipeline could continue throughout the year, according to the same Q2 2026 commentary by Yahoo Finance.
Dividend and valuation under scrutiny
Income-focused investors are watching Novartis dividend and valuation closely in light of the recent share-price swings and changing analyst views. According to GuruFocus on September 10, 2026, Novartis offers a dividend yield of 3.41 percent with a payout ratio of 71 percent, backed by a three-year dividend growth rate of 0.4 percent, which suggests a sustainable but slow-growing income stream.
The same analysis sees the stock trading at about 5.0 percent above its GF Value estimate of 130.94 dollars per share, at a spot price of 137.48 dollars on the New York listing used in that model, implying that Novartis stock is fairly valued rather than deeply discounted on those metrics, as stated by GuruFocus.
For investors, the tension between pipeline risk and dividend stability is now central. On one hand, Q2 2026 free cash flow of 5.6 billion dollars, cited in the same overview by Yahoo Finance, provides solid coverage for dividends and ongoing research spending.
On the other hand, the recent failures of pelacarsen and the muscle-wasting program underscore that future growth and returns depend heavily on the success of high-margin blockbuster candidates, making upcoming trial milestones critical for whether Novartis stock can justify the valuation implied by analyst targets such as HSBCs 136.00 dollars per share.
Stock stabilizes after sell-off on SIX Swiss Exchange
Price data from a recent session show the immediate market reaction and subsequent stabilization on the primary listing in Switzerland. Per a midday trading snapshot reported by finanzen.ch on September 10, 2026, Novartis shares were up 1.5 percent at 113.36 Swiss francs on the SIX Swiss Exchange, placing the stock among the gainers in the Swiss Market Index.
For investors tracking the primary Swiss listing, the recent pattern has been a record daily fall followed by a modest rebound, while U.S. investors in the New York-traded Novartis American Depositary Shares have seen the price trade slightly above intrinsic value estimates and within sight of analyst targets such as the 136.00 dollars level highlighted by HSBC, with consensus target data from MarketScreener indicating an average target around 153.34 dollars.
Novartis stock key data
- Company: Novartis AG
- ISIN: CH0012005267
- Ticker: NOVN
- Trading venue: SIX Swiss Exchange
- Price (as of September 10, 2026, 12:28): 113.36 CHF
- Market capitalization: 26,000,000,000 CHF (as of September 10, 2026)
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: SMI
